The 61 references in paper V. Arkhipov V., В. Архипов В. (2014) “Клиническая фармакология рофлумиласта // Clinical pharmacology of roflumilast” / spz:neicon:pulmonology:y:2012:i:2:p:90-98

1
Jeon Y., Heo Y., Kim C. et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell. Mol. Life Sci.
(check this in PDF content)
2
05; 62 (11): 1198–1220. 2.Boswell*Smith V., Spina D., Page C.P.Phosphodiesterase inhibitors. Br. J. Pharmacol. 2006; 147: S252–S257.
(check this in PDF content)
3
Uckert S., Kuthe A., Stief C.G., Jonas U. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. Wld J. Urol. 2001; 19: 14–22.
(check this in PDF content)
4
McIvor R.A. Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors. Eur. Respir. Rev. 2007; 16 (105): 105–112. Таблица 5 Наиболее частые НЯ при терапии рофлумиластом [58] РофлумиластПлацебо (n= 5 491)
(check this in PDF content)
5
0 мкг / сут, (n= 5 766) Любые нежелательные явления, n (%) Больные с НЯ3 873 (67,2)3 447 (62,8) Больные с СНЯ781 (13,5)782 (14,2) Умершие84 (1,5)86 (1,6) Выбывшие из исследования из-за НЯ824(14,3)503 (9,2) Нежелательные явления со стороны органов и систем, % Инфекции25,927,5 Риниты и фарингиты6,36,3 Инфекции нижних дыхательных путей3,84,3 Бронхиты3,13,5 Грипп2,52,4 Пневмония 1,82,0 НЯ, связанные с органами дыхания25,629,3 Обострение ХОБЛ19,823,1 Одышка 1,52,2 НЯ со стороны ЖКТ2210,7 Диарея 10,12,6 Тошнота5,21,4 НЯ, связанные с нервной системой10,75,5 Головная боль4,62,0 Головокружения2,41,2 НЯ, связанные с опорно
(check this in PDF content)
6
Erdogan S., Houslay M.D.Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem. J. 2003; 321 (Pt 1): 165–175.
(check this in PDF content)
7
Mehats C., Jin S.L., Wahlstrom J. et al. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J. 2003; 17: 1831–1841.
(check this in PDF content)
8
Giembycz M.A. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Exp. Opin. Invest. Drugs 2001; 10: 1361–1379.
(check this in PDF content)
9
Jin S.L., Conti M.Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFalpha responses. Proc. Natl Acad. Sci. USA 2002; 99: 7628–7633.
(check this in PDF content)
10
Robichaud A., Stamatiou P.B., Jin S.L. et al.Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor- mediated anaesthesia, a behavioural correlate of emesis. J. Clin. Invest. 2002; 110: 1045–1052.
(check this in PDF content)
11
Wang D., Cui X. Evaluation of PDE4 inhibition for COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2006; 1 (4): 373–379.
(check this in PDF content)
12
LeadDiscovery. 2006. Phosphodiesterase 4 (PDE4) & phosphodiesterase 5 (PDE5) inhibitors [online]. Accessed 16 June 2006. URL: http://www.leaddiscovery.co.uk/reports/ Phosphodiesterase*library.html
(check this in PDF content)
13
Hatzelmann A., Morcillo E.J., Lungarella G. et. al. The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2010; 23: 235–256.
(check this in PDF content)
14
Bethke T.D., Böhmer G.M., Hermann R. et al.Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J. Clin. Pharmacol. 2007; 47: 26–36.
(check this in PDF content)
15
Lahu G., Hünnemeyer A., Diletti E. et al. Population pharmacokinetic modelling of roflumilast and roflumilast N-Oxide by total phosphodiesterase 4 inhibitory activity and development of a population pharmacodynamicadverse event model. Clin. Pharmacokinet. 2010; 49: 589–606.
(check this in PDF content)
16
Nassr N., Lahu G., Hunnemeyer A. et al.Magnesium hydroxide / aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. J. Clin. Pharmacol. 2007; 47: 660–666.
(check this in PDF content)
17
Lahu G., Hunnemeyer A., Herzog R. et al.Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int. J. Clin. Pharmacol. Ther. 2009; 47: 236–245.
(check this in PDF content)
18
Lahu G., Hünnemeyer A., von Richter O. et al. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. J. Clin. Pharmacol. 2008; 48: 1339–1349.
(check this in PDF content)
19
Nassr N., Huennemeyer A., Herzog R. et al. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br. J. Clin. Pharmacol.
(check this in PDF content)
20
9; 68: 580–587. 20.von Richter O., Lahu G., Hunnemeyer A. et al. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin. Pharmacokinet. 2007; 46: 613–622.
(check this in PDF content)
21
Ram F.S. Use of theophylline in chronic obstructive pulmonary disease: examining the evidence. Curr. Opin. Pulm. Med. 2006;12 (2): 132–139.
(check this in PDF content)
22
Bennett J.A., Thompson Coon I., Pavord P. et al.The airway effects of stopping regular oral theophylline in patients with asthma. Br. J. Clin. Pharmacol. 1998; 45: 402–404.
(check this in PDF content)
23
Boswell*Smith V., Cazzola M., Page C.P.Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol. 2006; 117 (6):1237–1243.
(check this in PDF content)
24
Profita M., Sala A., Bonanno A. et al.Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010; 298 (2): L261–L269.
(check this in PDF content)
25
Brightling C.E., Monteiro W., Ward R. et al.Sputum eosinophilia and short–term response to prednisolone in chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2000; 356: 1480–1485.
(check this in PDF content)
26
Tenor H., Hatzelmann A., Church M.K. et al.Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br. J. Pharmacol. 1996; 118: 1727–1235.
(check this in PDF content)
27
Grootendorst D.C., Gauw S.A., Verhoosel R.M. et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62 (12): 1081–1087.
(check this in PDF content)
28
Jones N.A., Boswell*Smith V., Lever R., Page C.P.The eff ect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm. Pharmacol. Ther. 2005; 18: 93–101.
(check this in PDF content)
29
Hidi R., Timmermans S., Liu E. et al.Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur. Respir. J. 2000; 15: 342–349.
(check this in PDF content)
30
Au B.T., Teixeira M.M., Collins P.D., Williams T.J.Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br. J. Pharmacol. 1998; 123: 1260–1266.
(check this in PDF content)
31
Cortijo J., Villagrasa V., Navarrete C. et al. Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim. Br. J. Pharmacol. 1996; 119: 99–106.
(check this in PDF content)
32
Nadel J.A.Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 2000; 117 (5, Suppl. 2): S386–S389.
(check this in PDF content)
33
Fitzgerald M.F., Spicer D., McAulay A.E. et al. Roflumilast butnot methylprednisolone inhibited cigarette smokeinduced pulmonary inflammation in guinea pigs. Eur. Respir. J. Suppl. 2006; 663s: P3850.
(check this in PDF content)
34
Barnes N.C., Qiu Y.S., Pavord I.D. et al.Antiinflammatory effects of salmeterol / fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173 (7): 736–743.
(check this in PDF content)
35
Confalonieri M., Mainardi E., Della Porta R. et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583–585.
(check this in PDF content)
36
Keatings V., Jatakanon A., Worsdell Y. et al.Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 1997; 155: 548.
(check this in PDF content)
37
Leigh R., Pizzichini M.M., Morris M.M. et al.Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur. Respir. J. 2006; 27 (5): 964–971.
(check this in PDF content)
38
Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905–1917.
(check this in PDF content)
39
Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167–175. Архипов В.В. Клиническая фармакология рофлумиласта
(check this in PDF content)
40
Boszormenyi*Nagy G., Pieters W.R., Steffen H. et al.The effect of roflumilast treatment and subsequent withdrawal in patients with COPD [abstract]. Proc. Am. Thor. Soc. 2005; 2: A544.
(check this in PDF content)
41
Grootendorst D.C., Gauw S.A., Baan R. et al. Does a single dose of the phosphodieasterase 4 inhibitor, cilomilast (15 mg), induce bronchodilatation in patients with chronic obstructive pulmonary disease? Pulm. Pharmacol. Ther. 2003; 16: 115–120.
(check this in PDF content)
42
Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361 (9356): 449–456.
(check this in PDF content)
43
Rabe K.F., Bateman E.D., O'Donnell D. et al. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005; 366: 563–571.
(check this in PDF content)
44
Nycomed data on file.
(check this in PDF content)
45
Calverley P.M., Sanchez*Toril F., McIvor A. et al.Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176: 154–161.
(check this in PDF content)
46
Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–694.
(check this in PDF content)
47
Fabbri L.M., Calverley P.M.A., Izquierdo*Alonso J.L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374 (9691): 695–703.
(check this in PDF content)
48
Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann. Intern. Med. 2007; 146 (8): 545–555.
(check this in PDF content)
49
Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.
(check this in PDF content)
50
Burge P.S., Calverley P.M., Jones P.W. et al.Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Bг. Med. J. (Clin. Res. Ed.) 2000; 320 (7245): 1297–1303.
(check this in PDF content)
51
Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103.
(check this in PDF content)
52
Chapman K.R., Rabe K.F.Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease (COPD) concomitantly treated with tiotropium or salmeterol. Prim. Care Respir. J. 2010; 19: A12.
(check this in PDF content)
53
Rennard S.I., Calverley P.M., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir. Res. 2011; 12: 18.
(check this in PDF content)
54
Bateman E.D., Rabe K.F., Calverley P.M. et al.Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur. Respir. J. 2011; 38 (3): 553–560.
(check this in PDF content)
55
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (updated 2011). http:// www.goldcopd.org
(check this in PDF content)
56
Mahler D., Wells C.Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580–586.
(check this in PDF content)
57
Jones P.W., Harding G., Berry P. et al.Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 648–654.
(check this in PDF content)
58
Calverley P.M.A., Fabbri L.M., Rabe K.F., Mosberg H. Roflumilast in the treatment of COPD: a pooled safety analysis. In: Presented at the European Respiratory Society annual congress, Barcelona, Spain 18–22 Sept., 2010: Barcelona; 2010. Poster 4732.
(check this in PDF content)
59
Boswell*Smith V., Spina D.PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int. J. Chron. Obstruct. Pulm. Dis. 2007; 2: 121–129.
(check this in PDF content)
60
Rabe K.F.Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 2011; 163 (1): 53–67.
(check this in PDF content)
61
Wouters E.F.M., Teichmann P., Brose M. et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 181: A4473. Информация об авторе
(check this in PDF content)